Catalyst Pharmaceuticals Files 8-K

Ticker: CPRX · Form: 8-K · Filed: 2025-01-21T00:00:00.000Z

Sentiment: neutral

Topics: 8-K, financial-statements, exhibits

Related Tickers: CPRX

TL;DR

CPRX filed an 8-K, mostly standard financial docs. No major news.

AI Summary

On January 21, 2025, Catalyst Pharmaceuticals, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, indicating routine corporate disclosures rather than a specific material event. No new financial figures or significant business developments were detailed in the provided excerpt.

Why It Matters

This filing indicates routine corporate disclosures and the submission of financial statements and exhibits, which is standard for publicly traded companies.

Risk Assessment

Risk Level: low — The filing appears to be a routine disclosure of financial statements and exhibits, with no indication of significant new risks or events.

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing by Catalyst Pharmaceuticals, Inc.?

The primary purpose of this 8-K filing is to report 'Other Events' and to provide 'Financial Statements and Exhibits'.

When was the earliest event reported in this filing?

The earliest event reported in this filing was on January 21, 2025.

In which state is Catalyst Pharmaceuticals, Inc. incorporated?

Catalyst Pharmaceuticals, Inc. is incorporated in Delaware.

What is the principal executive office address for Catalyst Pharmaceuticals, Inc.?

The principal executive office address is 355 Alhambra Circle Suite 801 Coral Gables, Florida 33134.

Does this filing indicate any specific new product launches or regulatory approvals?

The provided excerpt of the 8-K filing does not detail any specific new product launches or regulatory approvals; it focuses on 'Other Events' and 'Financial Statements and Exhibits'.

From the Filing

0001193125-25-009573.txt : 20250121 0001193125-25-009573.hdr.sgml : 20250121 20250121163015 ACCESSION NUMBER: 0001193125-25-009573 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20250121 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20250121 DATE AS OF CHANGE: 20250121 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CATALYST PHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0001369568 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-33057 FILM NUMBER: 25542855 BUSINESS ADDRESS: STREET 1: 355 ALHAMBRA CIRCLE STREET 2: SUITE 801 CITY: CORAL GABLES STATE: FL ZIP: 33134 BUSINESS PHONE: (305) 529-2522 MAIL ADDRESS: STREET 1: 355 ALHAMBRA CIRCLE STREET 2: SUITE 801 CITY: CORAL GABLES STATE: FL ZIP: 33134 FORMER COMPANY: FORMER CONFORMED NAME: CATALYST PHARMACEUTICAL PARTNERS, INC. DATE OF NAME CHANGE: 20110215 FORMER COMPANY: FORMER CONFORMED NAME: Catalyst Pharmaceutical Partners, Inc. DATE OF NAME CHANGE: 20060719 8-K 1 d848918d8k.htm 8-K 8-K NASDAQ false 0001369568 0001369568 2025-01-21 2025-01-21     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     FORM 8-K     CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): January 21, 2025     CATALYST PHARMACEUTICALS, INC. (Exact Name Of Registrant As Specified In Its Charter)       Delaware   001-33057   76-0837053 (State or other jurisdiction of incorporation)   (Commission File Number)   (I.R.S. Employer Identification No.)   355 Alhambra Circle Suite 801 Coral Gables , Florida   33134 (Address of principal executive offices)   (Zip Code) Registrant’s telephone number, including area code: (305) 420-3200 Not Applicable Former Name or Former address, if changed since last report     Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:   ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)   ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)   ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR240.14d-2(b))   ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:   Title of Each Class   Name of Exchange on Which Registered   Ticker Symbol Common Stock, par value $0.001 per share   NASDAQ Capital Market   CPRX Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this Chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging Growth Company  ☐      If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.       Item 8.01 Other Events On January 21, 2025, the Company issued a press release announcing that its sub-licensee in Japan, DyDo Pharma, Inc., has launched FIRDAPSE ® Tablets 10 mg in Japan for the indication of improving muscle weakness in patients living with Lambert-Eaton myasthenic syndrome, or LEMS. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by re

View on Read The Filing